Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed Wants Across-The-Board Risk-Based Regulation For Diagnostics

This article was originally published in The Gray Sheet

Executive Summary

Under an AdvaMed plan for expanding FDA regulation of diagnostic tests, tests that consist of new or unproven biomarkers on new technology platforms would likely require a pre-market approval application
Advertisement

Related Content

FDA Dx Office Plans Pilot 510(k) ‘Triage’ Program For Early 2012
FDA Dx Office Plans Pilot 510(k) ‘Triage’ Program For Early 2012
FDA: Farewell To 510(k) Review For 30 Types Of Low-Risk Diagnostic Tests
AdvaMed Compiles List Of Tests That Should Be Exempt From FDA Review
AdvaMed Begets "AdvaMed Dx" For IVD-Focused Lobbying Effort
Guidance Pending To Help Clinical Labs Comply With FDA Manufacturing Regs
Would Expanded Lab-Test Regulation Overstep FDA’s Legal Limits?
Would Expanded Lab-Test Regulation Overstep FDA’s Legal Limits?
FDA Genetic Test Oversight Is On The Rise, But How Far Can It Go?
Industry Sees Room For Better Diagnostics Payments In Medicare Package

Topics

Advertisement
UsernamePublicRestriction

Register

MT027278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel